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Abstract
Objective: Mexican-American ancestry populations are at increased risk of non-alcoholic fatty 
liver disease (NALFD). Our objective was to determine whether loci in known and novel genes 
were associated with variation of aspartate aminotransferase (AST, n=3644), alanine 
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aminotransferase (ALT, n=3595) and gamma-glutamyl transferase (GGT, n=1577) by conducting 
the first genome-wide association study (GWAS) of liver enzymes, which commonly measure liver 
function, in Mexican-American ancestry.
Methods: Levels of AST, ALT, and GGT were determined by enzymatic colorimetric assays. A 
multi-cohort Mexican-American ancestry GWAS was performed. SNPs were tested for association 
with liver outcomes by multivariable linear regression using an additive genetic model. 
Association analyses were carried out separately in each cohort followed by a non-parametric 
meta-analysis.
Results: In the PNPLA3 gene, rs4823173 (P=3.44×10−10), rs2896019 (P=7.29×10−09), and 
rs2281135 (P=8.73×10−09), were significantly associated with AST levels. Although not genome-
wide significant, these same SNPs were the top hits for ALT (P=7.12×10−08, P=1.98×10−07, and 
P=1.81×10−07, respectively). The strong correlation (r2=1.0) for these SNPs indicates a single hit 
in the PNPLA3 gene. No genome-wide significant associations were found for GGT.
Conclusion: PNPLA3, a locus previously identified with ALT, AST, and NAFLD in European 
and Japanese GWAS, is also associated with liver enzymes in Mexican-American ancestry 
populations.
Keywords
aspartate aminotransferase; alanine aminotransferase; gamma-glutamyl transferase; genetic 
variance; Mexican-American ancestry
Introduction
Liver enzymes are commonly used to assess liver function and disease. High concentrations 
of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl 
transferase (GGT) are associated with various conditions, including non-alcoholic fatty liver 
disease (NAFLD), the most common cause of elevated liver enzymes in adults in the United 
States (1). NAFLD is often benign; however, it can lead to inflammation, fibrosis, and 
eventually, cirrhosis (2). NALFD is more common in Hispanic Americans than either 
African Americans or Caucasians (3, 4).
Plasma concentrations of liver enzymes are highly heritable (20-77%) (5), suggesting a 
genetic role that may help in interpretation of results and explain variation among 
individuals. Previous genome-wide association studies (GWAS) of liver enzymes in those of 
European (6, 7), Indian (7), and Japanese ancestry (8) identified candidate genes involved in 
various pathways, including glucose and lipid metabolism as well as inflammation and 
immunity. However, few studies have extensively examined the genetic contributions in 
Hispanics, a group at increased risk of NALFD (9), and no GWAS studies of liver enzymes 
or NAFLD have been conducted in individuals of Mexican-American ancestry.
The Genetics Underlying Diabetes in Hispanics (GUARDIAN) Consortium was formed to 
identify the genetic determinants of type 2 diabetes-related phenotypes in Hispanics (10), 
and is comprised of five family-based [BetaGene (11), Hypertension-Insulin Resistance 
Family study (HTN-IR) (12), Insulin Resistance Atherosclerosis Family Study (IRAS FS) 
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(13), Mexican-American Coronary Artery Disease study (MACAD) (14), and NIDDM-
Atherosclerosis Study (NIDDM-Athero) (15)] and two non–family-based studies [IRAS (16) 
and Troglitazone in the Prevention of Diabetes study (TRIPOD) (17)]. The majority of these 
studies also included measures of liver function, with measures of AST, ALT and GGT. The 
objective of this study was to determine whether loci in known and novel genes were 
associated with variation in AST, ALT and GGT levels in Mexican-American ancestry 
populations in the GUARDIAN Consortium by conducting the first GWAS of liver enzymes 
in individuals of Mexican-American ancestry.
Methods
Study Population
All participants provided written informed consent, and the institutional review boards at the 
respective institutions approved the study. Five cohorts of self-reported individuals of 
Mexican-American ancestry, ascertained on varying conditions, had measures of liver 
enzymes and were used in these analyses. Cohort descriptions can be found in the 
Supplementary Materials.
Outcome Variables and Covariates
Concentrations in IU/L of ALT, AST, and GGT were determined by enzymatic colorimetric 
assays. Age and sex were self-reported. Body mass index (BMI) was calculated as weight 
(kg)/height (m2).
Genotyping
All samples were genotyped on the Illumina HumanOmniExpress BeadChip, and alleles 
were called using GenomeStudio software (Illumina, San Diego, CA) (18, 19). Samples with 
call rates >0.98, single nucleotide polymorphisms (SNPs) with call rates >0.99, and minor 
allele frequency (MAF) >0.001 passed laboratory quality control (20), with 22,000 
additional SNPs manually reviewed for clustering accuracy. Samples were removed from 
analysis if the overall call rate was <0.98, if the samples were genetic outliers for sex and 
admixture proportions, if the samples were monomorphic , or if there was inconsistent 
fingerprinting from existing SNP data (21).The primary inferential SNPs did not exhibit 
differential missingness by trait, had a SNP call rate >98%, and did not depart from Hardy- 
Weinberg equilibrium expectations. Pedigrees were examined for consistency of stated 
family structure. Each SNP was examined for Mendelian inconsistencies using PedCheck 
(Program for Detecting Marker Typing Incompatibilities in Pedigree Data,http://
watson.hgen.pitt.edu/register/docs/pedcheck.html). and inconsistencies were converted to 
missing. A maximum of 659,222 SNPs were meta-analyzed.
Population Stratification
Population substructure was estimated using ADMIXTURE version 1.21 (http://
www.genetics.ucla.edu/software/admixture) at each study site based on SNPs that passed 
quality control [n = 117,347 linkage disequilibrium (LD)–pruned SNPs]. Data from the 
HapMap Project, including Mexican ancestry, were used as reference populations (21). 
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Admixture proportions were included as covariates in the tests of association with liver 
enzymes.
Statistical Analysis
All cohorts had measures of AST and ALT, while only HTN-IR and IRAS FS had data 
available for GGT. To best approximate normality and homogeneity of variance in all 
cohorts, levels of AST, ALT and GGT were log-transformed. There are 3757 individuals for 
genotyping. Variance component analyses as implemented in the GWAF (Genome-Wide 
Association analyses with Family) (22) or SOLAR (Sequential Oligogenic Linkage Analysis 
Routines) (23) programs were used to test for association in family cohorts and linear 
regression analyses as implemented in QSNPGWA (http://github.com/guyrt/WFUBMC) 
were used to test for association in the non-family-based cohort. SNPs were tested for 
association with liver enzymes using an additive genetic model adjusted for age, sex, BMI, 
admixture proportions, family structure, and recruitment center (for multi-center studies). 
Conditional analyses were performed for significant loci with multiple uncorrelated variants 
by including the most significant variant as an additional covariate. For significant 
uncorrelated loci, SNP-age and SNP-sex interactions were examined.
Association analyses were carried out separately in each cohort followed by a non-
parametric meta-analysis as implemented in METAL (http://www.sph.umich.edu/csg/
abecasis/metal). For each liver enzyme outcome, a weighted, fixed-effects meta-analysis was 
calculated, weighting by cohort sample size due to different study design and ascertainment 
criteria, and correcting for genomic control inflation factors. A MAF >0.01 filter resulted in 
659,222 SNPs for AST, 659,211 SNPs for ALT, and 655,023 SNPs for GGT. Genome-wide 
significance was determined at P<1×10−8, allowing for a Bonferroni adjustment for 106 
SNPs tested and three liver enzyme outcomes.
Known variants (n=31) from previous liver enzyme and NAFLD GWAS that were available 
in the GUARDIAN Consortium genotype data were examined for association with AST, 
ALT and GGT. Associations were reported for enzyme specific variants (e.g. AST 
associations for reported AST variants), and associations with all liver enzymes were 
reported for previously reported NAFLD/NASH variants. If reported variants in the same 
gene had a LD > 0.80 in the HapMap Project Mexican population, then only the variant with 
the highest p-value was reported. Significance for the known variants was determined at 
P<0.05. We did not correct for multiple testing due to a priori hypotheses based on well-
known associations.
Results
Characteristics of the study participants are shown in Table 1. Mean age ranged from 35-41 
years, the majority was female, and mean BMI ranged between 28-31 kg/m2. Mean levels of 
AST, ALT and GGT were within normal ranges (10-40 IU/L, 7-56 IU/L, and 0-45 IU/L, 
respectively.
The P-P plot of P values (Supplementary Figure S1) from the meta-analysis did not suggest 
any systematic biases, such as those related to population stratification. We identified three 
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SNPs, within the PNPLA3 (patatin-like phospholipase domain containing 3) locus on 
chromosome 22, attaining genome-wide significance (P < 1 × 10−8) with AST levels (Table 
2, Figure 1A, Supplementary Table S1) with a positive effect direction. These same three 
SNPs, rs4823173, rs2896019, and rs2281135, were also the top signals for ALT levels 
(Table 2, Figure 2B, Supplementary Table S2) in the same positive effect direction, 
approaching genome-wide significance (P<7.12 × 10−8). There were no genome-wide 
significant associations found with GGT levels (Table 2, Figure 2C, Supplementary Table 
S3), with the top variants representing ZNF804A (Zinc protein finger 804A) and USP24P1 
(ubiquitin specific peptidase 24 pseudogene 1). There were no significant rs482173xage 
(p=0.60 and p=0.47) or rs482173xsex interactions (p=0.54 and p=0.53) for AST and ALT, 
respectively.
There was perfect LD between rs4823173, rs2896019, and rs2281135 (r2=1.0 for all 
correlations) in the HapMap Project Mexican population; combined with the regional plot 
using the 1000 genomes AMR population, this indicates a single hit on the PNPLA3 gene 
(Figure 2). For the significant hit in the PNPLA3 gene, the OmniExpress imputed data from 
the PNPLA3 gene region on Chromosome 22 was pulled as it included rs738409, the most 
commonly reported significant SNP in the literature. To assess the evidence for multiple 
independent association signals within PNPLA3 for AST levels, association with rs4823173 
(the most significant SNP in the meta-analysis) were tested after adjusting for rs738409. 
After adjusting for rs738409 along with the standard covariates, rs4823173 was no longer 
statistically significant (p=0.32). The loss of significance of rs4823173 after adjustment for 
rs738409, the top literature SNP, was consistent with the LD among the SNPs in this 
population (r2=0.84) and does not provide evidence for multiple association signals.
Thirty one variants reported in other liver enzyme or NAFLD/NASH GWAS in European (6, 
7, 24-28), Indian(7, 28), Japanese(8, 29), and Korean (30) populations (Table 3) were 
examined. Beyond the PNPLA3 gene, several SNPs associated with NAFLD showed 
significant associations with liver enzymes in the Mexican-American ancestry populations. 
rs3761472 in SAMM50 was significantly associated with AST, ALT and GGT (P=9×10−4, 
3×10−4, and 0.01, respectively), and variants in PARVB were significantly associated with 
AST (P=3.0×10−4) and GGT (P=0.02) levels. For previous enzyme specific variants, prior 
ALT-associated variants rs11597086 in CHUK (P=0.03) and rs11597390 in CPN1 (P=0.02) 
were significantly associated with ALT. In addition, several prior GGT-associated variants 
were associated with GGT levels in individuals of Mexican-American ancestry: 7310409 in 
HNF1A (P=0.02), rs4820599 in GGT1 (P=0.04), rs4547811 in ZNF827 (P=0.03), rs944002 
in C14orf73 (P=1.0×10−4), and rs339969 and rs340005 in RORA (P=0.02 for both). Aside 
from the variants in PNPLA3 and SAMM50, no prior AST variants were significantly 
associated with AST in individuals of Mexican-American ancestry.
Discussion
We conducted the first GWAS of liver enzymes in individuals of Mexican-American 
ancestry, a population at increased risk of NAFLD. This study provided evidence that 
PNPLA3 is associated with liver function in Mexican-Americans. We report genotyped data 
and therefore may limit our power to detect associations not included in our genotyping 
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array by not imputing. However, while previous candidate gene studies in Hispanics have 
reported associations between variants in PNPLA3 and increased AST and ALT levels 
(31-35), we report a genome-wide significant association (P < 1 × 10−8) with AST and near 
significant association with ALT. There was high LD between rs4823173 with rs738409 in 
this population (r2=0.84), the most commonly reported PNPLA3 SNP in the literature, 
indicating that there is likely one association signal between PNPLA3 and levels of AST and 
ALT. These results demonstrate that PNPLA3, a locus previously identified by GWAS for 
ALT and AST in European(6, 7), Indian(7), and Japanese ancestry (8), is associated with 
liver function in Hispanics as well.
The PNPLA3 gene is located on chromosome 22 and has been implicated in genetic studies 
of liver function in both GWAS (6-8, 24, 26-30) and candidate gene (33, 36-40) studies 
across several ancestries. The PNPLA3 protein is expressed in both adipocytes and 
hepatocytes (41). PNPLA3 mediates triacylglycerol hydrolysis in adipocytes (42), and may 
be involved in energy storage and usage.
We confirmed several previously reported NAFLD SNPs and their associations with AST, 
ALT, and GGT. Variants in SAMM50, which is in the same genetic region as PNPLA3 and 
is involved in the biogenesis of mitochondria, and PARVB, involved in lipid accumulation 
and fibrosis, were previously associated with NAFLD/NASH and were associated with AST, 
ALT and/or GGT in our cohort of individuals of Mexican-American ancestry. Recently, in a 
candidate gene study in a Mexican population with NAFLD, variants in SAMM50 have been 
associated with increased with AST levels (35) Interestingly, using the browsers set up by 
the Genotype-Tissue Expression (GTEx) project (43), we found that our associated intronic 
variant rs4823173, which is in strong LD with PNPLA3 rs738409, is located near an exon, 
and SAMM50 expression, not PNPLA3, is affected by rs4821373in subcutaneous adipose 
tissue. These pathways could indicate that fatty liver is still ongoing and possibly 
progressing in this largely overweight/obese population with increasing accumulation of 
adipose tissue. In addition, we confirmed several prior enzyme-specific associations in our 
populations. For ALT, associations were found for variants in or near genes involved in 
inflammation and possibly modulation of insulin resistance through NF-kB (CPN1-CHUK 
gene cluster). For GGT, associations in or near genes involved in glutathione metabolism 
(GGT1), inflammation (HNF1A, RORA) and lipid metabolism (HNF1A), and several other 
genes with cardiombetabolic associations but with currently unknown functionality 
(ZNF827, C14orf73). Interestingly, we did not find any other significant associations with 
AST levels, indicating that PNPLA3, SAMM50 and PARVB, all previously associated with 
NAFLD, may be the largest contributors to AST levels of the variants studied in individuals 
of Mexican-American ancestry.
Similar to other studies (36, 37), we report a higher minor allele frequency in individuals of 
Mexican-American ancestry compared to individuals of European, African American, or 
Asian ancestry. The similar effect size reported across ancestries (36) but the higher affect 
allele frequency may explain, in part, the higher AST and ALT levels in Hispanics (4, 44), as 
well as Hispanics greater risk of NAFLD (3, 4, 44, 45). One limitation to our study is that 
we only have liver density measures in one cohort (IRAS FS) so we could not extend our 
GWAS to include NAFLD as an outcome. However, the IRAS FS has previously reported 
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highly significant associations between rs738409 in PNPLA3 and NAFLD (36, 40). To the 
extent that our associations with higher AST or ALT levels could be indicative of pre-
clinical liver inflammation in Hispanics, our findings suggest that the presence of the 
PNPLA3 risk alleles could indicate increased risk of NAFLD within this population.
Several studies have reported sex and age differences in the association of PNPLA3 variants 
and liver enzymes, where younger females had an association with higher ALT and males 
had an association with higher AST levels (32, 38). We did not see any significant sex or age 
interactions with rs4823173. This could be due to differences in ancestry, or the younger age 
of our population compared to the other studies, as the age effect was seen mostly in women 
over 50 years of age. In addition, our population was majority female, so differences by sex 
may have been harder to discern.
We did not see any genome-wide significant associations with GGT. This is most likely due 
to the smaller sample size and resulting decreased power. When comparing our results to 
previously published loci, we found an association between rs944002 in C14orf73 (7, 25) 
for GGT (P=5.83 × 10−5). C14orf73, also known as EXOC3L4 (exocyst complex 
component 3 like 4), is expressed in the liver, and could indicate another genetic link to 
variation in liver enzymes.
In conclusion, we found that SNPs in the PNPLA3 gene, rs4823173, rs2896019, and 
rs2281135 were significantly associated with AST levels. Although they did not reach the 
threshold for significance in this study, these same three SNPs in the PNPLA3 gene were the 
top hits with ALT. The strong LD for these SNPs, as well as with rs738409, indicates a 
single hit in the PNPLA3 gene. These results demonstrate that PNPLA3, a locus previously 
identified with ALT, AST, and NAFLD/NASH in other ancestries, is associated with liver 
function in Hispanics as well.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study Importance:
What is already known about this subject?
• Previous genome-wide association studies of liver enzymes in those of 
European, Indian, and Japanese ancestry identified candidate genes involved 
in various pathways, including glucose and lipid metabolism as well as 
inflammation and immunity.
What does this study add?
• Few studies have extensively examined the genetic contributions of liver 
enzymes in Hispanics, a group at increased risk of non-alcoholic fatty liver 
disease.
• This is the first GWAS of liver enzymes or NAFLD in individuals of 
Mexican-American ancestry.
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Figure 1. 
Genome-wide Manhattan plots for the GUARDIAN Consortium meta-analysis. SNPs above 
the red line were genome-wide significant at P < 1 × 10−8. A. Results for AST of 659,222 
SNPs indicate a genome-wide significant loci for PNPLA3 (P=3.44 × 10 −10). B. Results for 
ALT of 659,211 SNPs. C. Results for GGT of 655,023 SNPs.
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Figure 2. 
Regional plot of the PNPLA3 locus in the GUARDIAN Consortium meta-analysis for AST. 
Genotyped SNPs are plotted with their meta-analysis p-values (−log10) according to their 
chromosomal position (hg19). The purple diamond represents rs4823173, the top variant in 
the meta-analysis for AST; red circles represent rs2896019 and rs2281135 (r2≥0.80).
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Table 1.
Characteristics of the GUARDIAN Consortium meta-analysis cohorts.
BetaGene HTN-IR IRAS FS MACAD TRIPOD
Sample Size 1195 689 1034 714 125
Age 34.69 ± 7.92 37.28 ± 14.13 40.60 ± 13.7 34.49 ± 8.86 34.72 ± 6.26
Female (%) 71.72 58.90 58.90 56.74 100.00
BMI (kg/m2) 29.58 ± 6.09 28.73 ± 5.45 28.30 ± 5.80 28.92 ± 5.11 30.50 ± 5.43
AST (IU/L) 23.21 ± 11.60 24.57 ± 13.09 19.10 ± 8.90 24.86 ± 10.92 18.98 ± 8.10
ALT (IU/L) 36.83 ± 24.56 35.19 ± 23.88 11.30 ± 9.90 28.86 ± 20.65 26.21 ± 16.40
GGT (IU/L) NA 31 ± 25.51 39.40 ± 43.70 NA NA
Data are mean ± SD unless otherwise indicated. NA, not applicable. BMI, body mass index. AST, aspartate aminotransferase. ALT, alanine 
aminotransferase. GGT, gamma-glutamyl transferase. Data on GGT was not available in BetaGene, TRIPOD nor MACAD.
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Table 2.
Top hits in the GUARDIAN Consortium liver enzyme meta-analysis by trait (P < 1 × 10−7).
SNP Chromosome Position1 Gene Alleles2 MAF Trait P-value
rs4823173 22 44328730 PNPLA3 A/G 0.42 AST 3.44 × 10−10
rs2896019 22 44333694 PNPLA3 G/T 0.43 AST 7.29 × 10−9
rs2281135 22 44332570 PNPLA3 A/G 0.43 AST 8.73 × 10−9
rs178571 6 136346130 PDE78 T/C 0.03 AST 3.21 × 10−8
rs1883350 22 44328043 PNPLA3 T/C 0.49 AST 5.22 × 10−7
rs4823173 22 44328730 PNPLA3 A/G 0.42 ALT 7.12 × 10−8
rs2281135 22 44332570 PNPLA3 A/G 0.43 ALT 1.81 × 10−7
rs2896019 22 44333694 PNPLA3 G/T 0.43 ALT 1.98 × 10−7
rs9601485 13 81475442 intergenic T/C 0.12 ALT 3.17 × 10−7
rs10497655 2 185462041 ZNF804A C/T 0.30 GGT 3.10 × 10−7
rs9511099 13 19591944 USP24P1 G/T 0.21 GGT 3.72 × 10−7
rs10458877 11 15941099 intergenic T/C 0.13 GGT 8.59 × 10−7
SNP, single nucleotide polymorphism. MAF, minor allele frequency. AST, aspartate aminotransferase. ALT, alanine aminotransferase. GGT, 
gamma-glutamyl transferase.
For BetaGene, there are n=1191 for AST and n=1193 for ALT, respectively; for IRAS FS, there are n=925 n=878, and n=888 samples with AST, 
ALT, and GGT respectively; sample size for HTN is n=688 for ALT; and sample size for ALT is n=711 in MACAD.
1.
Build hg19.
2.
Minor/Major allele.
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Table 3.
GUARDIAN Consortium meta-analysis P values for regions reported in other liver enzyme or NAFLD/NASH 
GWAS. P value is listed for the GUARDIAN Consortium meta-analysis.
Gene SNP Previously
Associated GWAS
Traits
AST
GUARDIAN
Consortium P-
value
ALT
GUARDIAN
Consortium P-
value
GGT
GUARDIAN
Consortium P-
value
PNPLA3 rs2896019
rs381062
AST 9,30, ALT9,10,30,NAFLD/NASH9,29,31 P=7.29×10−9
P=0.78
P=1.98×10−7
P=0.62
P=0.008
P=0.89
SAMM50 rs738491
rs3761472
ALT30
NAFLD/NASH29
P=0.11
P=9×10−4
P=0.08
P=3×10−4
P=0.37
P=0.01
CHUK rs11597086 ALT30 P=0.03
CPN1 rs11597390 ALT9,30 P=0.02
ST6GALNAC3 rs4949718 ALT32 P=0.81
CELF2 rs596406 AST28,ALT32 P=0.92 P=0.59
GOT1 rs17109512 AST28 P=0.28
ST6GALNAC3 rs4949718 AST28 P=0.64
ZP4 rs2499604 AST26 P=0.64
PZP rs6487679 AST26 P=0.45
HNF1A rs1169313
rs1169288
rs7310409
GGT9,27,30 P=0.10
P=0.29
P=0.02
GGT1 rs4820599
rs5751901
GGT 9,27,30 P=0.04
P=0.09
C2ofr16 rs1260326 GGT9 P=0.23
ZNF827 rs4547811 GGT9 P=0.03
ITGA1 rs4074793 GGT9 P=0.93
MLXIPL rs17145750 GGT9 P=0.81
C14orf73 rs944002 GGT9,27 P=1.0×10−4
RORA rs339969
rs340005
GGT9,27 P=0.02
P=0.02
CD276 rs8038465 GGT9 P=0.59
FUT2 rs516246 GGT9 P=0.74
FDFT1 rs2645424 NAFLD/NASH26 P=0.09 P=0.77 P=0.70
PARVB rs5764455
rs6006611
NAFLD/NASH29 P=0.72
P=3.0×10−4
P=0.26
P=0.08
P=0.02
P=0.75
SLC38A8 rs11864146 NAFLD/NASH26 P=0.77 P=0.80 P=0.72
GCKR rs780094 NAFLD/NASH29 P=0.33 P=0.39 P=0.34
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